Truist reiterates Buy on Collegium Pharmaceutical stock By Investing.com

Truist reiterated a Buy on Collegium Pharmaceutical after its $650 million Azstarys acquisition, which adds roughly 750,000 prescriptions, extends IP protection to 2037, and is expected to be immediately EBITDA-accretive with more than $50 million in annual synergies. Truist sees Azstarys peaking at about $400 million in sales by 2036, complementing Jornay PM and supporting the company’s expanded ADHD salesforce. The company also reported Q4 2025 EPS of $2.04 versus $2.14 expected and revenue of $205.45 million versus $207.07 million expected, a modest miss offset by bullish analyst commentary.

Analysis

The setup is less about a single product win than about lowering the volatility of COLL’s earnings base. By layering a daytime ADHD asset onto an already entrenched nighttime franchise, the company is turning one salesforce into a broader prescriber-share capture machine; that should improve call efficiency, reduce CAC per script, and make the revenue mix look more like a platform than a one-product story. The market may still be underwriting COLL as a post-expiry cashflow name, when the real optionality is that the combined ADHD footprint can extend the growth runway well beyond the next 12 months.

The second-order beneficiary is the commercial execution model: synergies here are likely to show up first in SG&A leverage, not just headline EBITDA, because rep density and shared physician touchpoints can scale faster than COGS savings. That matters because the acquisition price implies the market is paying for visible script inventory while underappreciating the distribution advantage if cross-selling works. On the other side, smaller ADHD competitors and generic-channel intermediaries are the likely losers as COL L can defend share with broader access to the same prescribers and payer relationships.

The main risk is integration timing, not strategic fit. The stock can rerate on a 6–12 month horizon only if management proves that incremental scripts are additive rather than cannibalistic and that the synergy math survives payer pushback or channel disruption. Any sign of margin dilution, slower-than-expected refill retention, or a weaker-than-hoped launch curve could compress the multiple quickly because the thesis is now more dependent on execution than on portfolio quality alone.

Contrarian view: consensus may be overpricing the near-term accretion and underpricing the risk that the deal simply pulls forward growth rather than creating durable new demand. If the combined franchise stalls after the initial launch window, the market will likely re-rate COL L back toward a mid-teens EBITDA multiple rather than rewarding it as a growth platform. That creates a clean asymmetry: the upside is multiple expansion on proof of commercial leverage; the downside is de-rating if the acquisition is seen as financial engineering with limited organic incrementality.

Key Decisions for Investors

• Long COLL into the next 1-2 quarterly updates; target a 6-12 month window where proof of cross-selling and SG&A leverage can drive multiple expansion. Risk/reward is attractive if management shows even modest script acceleration, but cut exposure if launch KPIs miss by a meaningful margin.
• Use call spreads on COLL for a defined-risk upside view over 3-6 months. The catalyst stack is front-loaded, but the main risk is a post-announcement fade if investors decide the acquisition is already fully reflected in the stock.
• Pair trade: long COLL / short a basket of smaller ADHD or specialty-pharma commercial names with weaker distribution leverage over 6-9 months. The thesis is that rep-density and shared physician access will compound faster at COLL than at less integrated peers.
• If COLL rallies sharply on headline accretion alone, fade part of the move with a tight stop and wait for operational proof. The market may be paying today for synergy claims that only become credible after two reporting cycles.
• For event-driven accounts, buy on any pullback toward support after the first post-deal digestion period; the risk/reward improves if the market gives back the initial optimism without any fundamental negative update.